Pyxis Oncology, Inc. (PYXS)

NMS – Цена в реальном времени. Валюта: USD

2.77

+0.54 (24.22%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

2.77

+0.00 (0.00%)

После закрытия: Jun 26, 2026, 7:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Pyxis Oncology, Inc. (PYXS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Видео

No Data

Пресс-релизы

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Search stocks

Pyxis Oncology, Inc. (PYXS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Видео

No Data

Пресс-релизы

Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity